Next 10 |
home / stock / lzagy / lzagy news
NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today ...
2024-04-24 10:00:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio meaningfully beat the benchmark MSCI EAFE Index, as well as the seconda...
2024-04-24 03:45:00 ET Summary The MSCI ACWI ex-US Index was up 4.69% in the first quarter with a mixture of positive and negative elements. Performance of Economic Sectors were mixed as well. The best performance came from Information Technology while the worst was Consumer Stapl...
2024-04-04 13:20:24 ET Summary Reflecting Lonza's Vacaville acquisition, we increased our sales and EBITDA expectations. The company has an ongoing buyback and a progressive dividend per share. We positively view the new CEO appointment. This removed an overhang of Lonza's equ...
2024-04-02 05:21:07 ET Read the full article on Seeking Alpha For further details see: Lonza appoints new CEO
2024-03-20 06:14:16 ET Swiss contract drug manufacturer Lonza ( OTCPK:LZAGF ) ( OTCPK:LZAGY ) has agreed to acquire a large-scale biologics manufacturing site in California from Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) for $1.2B in cash.... Read the full article on Seekin...
2024-02-11 12:00:03 ET More on Eli Lilly, Novo Nordisk, etc. Will Eli Lilly and Company Become A Trillion-Dollar Baby? Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade) Eli Lilly and Co (LLY) Q4 2023 Earnings Conference Call Transcript ...
2024-01-27 10:40:00 ET Summary Lonza Group aims to increase revenue by double digits by 2028 through aggressive expansion in the CDMO space. Lonza expects to increase its EBITDA margin to 32%-34% by 2028 and maintain a low debt ratio. The company plans to generate 25% of its r...
2024-01-26 13:14:05 ET Lonza Group AG (LZAGY) Q4 2023 Earnings Conference Call January 26, 2024, 08:00 AM ET Company Participants Albert Baehny - CEO ad Interim and Chairman of the Board of Directors Philippe Deecke - CFO Conference Call Participants Rich...
2024-01-26 11:52:39 ET More on Lonza Lonza not planning to manufacture GLP-1 drugs: report Historical earnings data for Lonza Group Dividend scorecard for Lonza Group Financial information for Lonza Group Seeking Alpha’s Quant Rating on Lonza G...
News, Short Squeeze, Breakout and More Instantly...
Lonza Group AG ADR Company Name:
LZAGY Stock Symbol:
OTCMKTS Market:
NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today ...
Wednesday, Roche Holding AG (OTC:RHHBY) entered into a definitive agreement with Lonza Group Ltd (OTC:LZAGF) (OTC:LZAGY). Under...
FFW Corp. (FFWC) is expected to report for Q2 2024 ResMed Inc. (RMD) is expected to report $1.81 for Q2 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2023-12-31 ChoiceOne Financial Services Inc. (COFS) is expected to report $0.64 for Q4 2023 First ...